Université Paris Cité, Institut Cochin, CNRS, INSERM, Paris 75014, France.
Université Paris Cité, Institut Cochin, CNRS, INSERM, Paris 75014, France.
EBioMedicine. 2023 Sep;95:104740. doi: 10.1016/j.ebiom.2023.104740. Epub 2023 Aug 1.
To resist the autoimmune attack characteristic of type 1 diabetes, insulin producing pancreatic β cells need to evade T-cell recognition. Such escape mechanisms may be conferred by low HLA class I (HLA-I) expression and upregulation of immune inhibitory molecules such as Programmed cell Death Ligand 1 (PD-L1).
The expression of PD-L1, HLA-I and CXCL10 was evaluated in the human β cell line, ECN90, and in primary human and mouse pancreatic islets. Most genes were determined by real-time RT-PCR, flow cytometry and Western blot. Activator and inhibitor of the AKT signaling were used to modulate PD-L1 induction. Key results were validated by monitoring activity of CD8+ Jurkat T cells presenting β cell specific T-cell receptor and transduced with reporter genes in contact culture with the human β cell line, ECN90.
In this study, we identify tryptophan (TRP) as an agonist of PD-L1 induction through the AKT signaling pathway. TRP also synergistically enhanced PD-L1 expression on β cells exposed to interferon-γ. Conversely, interferon-γ-mediated induction of HLA-I and CXCL10 genes was down-regulated upon TRP treatment. Finally, TRP and its derivatives inhibited the activation of islet-reactive CD8+ T cells by β cells.
Collectively, our findings indicate that TRP could induce immune tolerance to β cells by promoting their immune evasion through HLA-I downregulation and PD-L1 upregulation.
Dutch Diabetes Research Foundation, DON Foundation, the Laboratoire d'Excellence consortium Revive (ANR-10-LABX-0073), Agence Nationale de la Recherche (ANR-19-CE15-0014-01), Fondation pour la Recherche Médicale (EQ U201903007793-EQU20193007831), Innovative Medicines InitiativeINNODIA and INNODIA HARVEST, Aides aux Jeunes Diabetiques (AJD) and Juvenile Diabetes Research Foundation Ltd (JDRF).
为了抵抗 1 型糖尿病的自身免疫攻击,产生胰岛素的胰腺β细胞需要逃避 T 细胞的识别。这种逃避机制可能是由低 HLA Ⅰ类(HLA-I)表达和上调免疫抑制分子如程序性细胞死亡配体 1(PD-L1)赋予的。
评估了人β细胞系 ECN90 以及原代人和小鼠胰腺胰岛中 PD-L1、HLA-I 和 CXCL10 的表达。大多数基因通过实时 RT-PCR、流式细胞术和 Western blot 确定。使用 AKT 信号的激活剂和抑制剂来调节 PD-L1 的诱导。通过监测在接触培养中与人类β细胞系 ECN90 接触时呈现β细胞特异性 T 细胞受体并转导报告基因的 CD8+ Jurkat T 细胞的活性,验证了关键结果。
在这项研究中,我们确定色氨酸(TRP)是通过 AKT 信号通路诱导 PD-L1 诱导的激动剂。TRP 还协同增强了干扰素-γ暴露下β细胞 PD-L1 的表达。相反,TRP 处理可下调干扰素-γ介导的 HLA-I 和 CXCL10 基因的诱导。最后,TRP 及其衍生物抑制了β细胞对胰岛反应性 CD8+T 细胞的激活。
总的来说,我们的研究结果表明,TRP 通过下调 HLA-I 和上调 PD-L1 来促进β细胞的免疫逃避,从而诱导对β细胞的免疫耐受。
荷兰糖尿病研究基金会、DON 基金会、卓越实验室联盟 Revive(ANR-10-LABX-0073)、法国国家研究署(ANR-19-CE15-0014-01)、法国医学研究基金会(EQ U201903007793-EQU20193007831)、创新药物倡议 INNODIA 和 INNODIA HARVEST、青少年糖尿病援助协会(AJD)和青少年糖尿病研究基金会有限公司(JDRF)。